AstraZeneca vaccine safety: EMA boss gives update on vaccine review – statement in full

AstraZeneca vaccine safety: EMA boss gives update on vaccine review – statement in full

AstraZeneca: Expert discusses 'risk' with jab suspensions

When you subscribe we will use the information you provide to send you these newsletters.Sometimes they’ll include recommendations for other related newsletters or services we offer.Our Privacy Notice explains more about how we use your data, and your rights.You can unsubscribe at any time.

The update from the EMA comes as a number of countries moved to stop administering the vaccine over the last few days. Germany, Italy, France, Cyprus, Luxembourg and others have all stopped use of the vaccine until further information is available. The UK-manufactured Oxford/AstraZeneca jab has been administered to about 17million people in the EU and UK, with the overall total of people developing blood clots amounting to just 37. 

Emer Cooke, EMA Executive Director, said: “We have pulled together an ad hoc meeting again today to help us evaluate these cases with all the surrounding information that the member states will have.

“The experts will then carry on their assessment and again will meet on Thursday to come to a conclusion on the full information that has been gathered and to advise us as to whether there are any further actions that need to be taken.

“We will inform the public of the outcome immediately after this meeting.

“Our experts are working tirelessly to carry out this assessment as quickly as possible, but it needs a scientific evaluation, we need to have the facts first, we cannot come to a conclusion until we have done a thorough scientific analysis and we owe it to the European citizens to deliver this clear and science-based response.”

Experts will be meeting on Thursday to draw their conclusions on the Oxford/AstraZeneca vaccine and the committee’s conclusions will be made public immediately afterwards.

Ms Cooke said the organisation remains convinced that the benefits of the AstraZeneca vaccine outweigh the risk of side-effects. 

She said there is no indicated that the estimated 17million jabs delivered by the firm have caused these incidents of blood clots. 

Ms Cook also previously states the number of clotting cases doesn’t seem to be higher than average in the general population. 

She said: “We know that many thousands of people develop thousands of clots annually for many different reasons.”

Source: Read Full Article